Farmanguinhos / Fiocruz

What Farmanguinhos / Fiocruz does

Farmanguinhos (Instituto de Tecnologia em Fármacos) is Brazil's federal pharmaceutical laboratory, established in 1976 as a unit of the Fundação Oswaldo Cruz (Fiocruz) under the Brazilian Ministry of Health. The institute operates as a government state entity that manufactures and supplies essential medicines exclusively to the Brazilian public health system (Sistema Único de Saúde, SUS), fulfilling 100% of Ministry of Health purchase orders through public procurement channels. Its commercial activity is restricted to public-sector supply; there are no private retail or commercial distribution channels.

The product portfolio spans nine antiretrovirals (including Dolutegravir 50mg + Lamivudina 300mg, Efavirenz, Zidovudine, and Atazanavir), four tuberculostatics (ethionamide, isoniazid, isoniazid+rifampicin, and a 4-in-1 fixed-dose combination), three antimalarials (primaquine, chloroquine, and artesunate+mefloquine), medications for nine neglected tropical diseases including schistosomiasis, Chagas disease, and filariasis, plus Pramipexol for Parkinson's disease (designated a national reference drug by ANVISA in 2023). Production technology centers on fixed-dose combinations, orodispersible pediatric tablets, double-layer compressed tablets acquired through the ViiV Healthcare/GSK alliance, and patented isoniazid derivatives filed in the US, India, China, Europe, and Brazil. A new 750 m² tuberculostatic production line inaugurated in 2023 added 150 million units/year of capacity, enabling TB medicine deliveries of over 80 million units in 2023.

The business model is government budget allocation rather than commercial revenue: Farmanguinhos is funded through the Brazilian Ministry of Health to provide medicines that the private sector does not profitably supply, particularly for neglected diseases. Strategic alliances with ViiV/GSK (Dolutegravir technology transfer), Bayer (Nifurtimox for Chagas), and the international Pediatric Praziquantel Consortium position the institute within a global public-health innovation network that includes WHO/PAHO, EMA, DNDi, and MMV. The organization also operates educational programs (graduate and residency), the CIBS innovation center for biodiversity-based pharmaceuticals, and the Revista Fitos scientific journal.

Name

Farmanguinhos / Fiocruz

Legal name

Instituto de Tecnologia em Fármacos (Farmanguinhos/Fiocruz)

Website

https://far.fiocruz.br

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Farmanguinhos is Brazil's federal pharmaceutical laboratory under Fiocruz and the Ministry of Health, supplying essential medicines — antiretrovirals, tuberculostatics, antimalarials, and treatments for nine neglected tropical diseases — exclusively to the Brazilian public health system (SUS) through government procurement.

Ownership category

akta.pro rank

Product category

Public Pharmaceutical Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Botanical Biopesticides & Plant Extracts (Essential Oils, Neem, Pyrethrins) (AFABAEAF)

akta.pro secondary industry

Medicinal Plant Farming (Botanical/Pharmaceutical Crops) (AFAGAGAE)

Keywords

• Pharmaceutical manufacturing
• Antiretroviral medications
• Public health supply
• Neglected tropical diseases
• Fixed-dose combinations

Headquarters

HQ city

Rio de Janeiro

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Government Budget Allocation (Ministry of Health / SUS): Farmanguinhos is a federal public institution (Laboratório Farmacêutico Federal) under Fiocruz and the Brazilian Ministry of Health. It operates on government budget allocations and fulfills purchase orders from the Ministry of Health for the Sistema Único de Saúde (SUS). The institute does not sell commercially to private customers — all production is directed to the public health system. Funding comes from federal government health budgets rather than commercial revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Farmanguinhos is a federal pharmaceutical laboratory that manufactures essential medicines (antiretrovirals, tuberculostatics, antimalarials, anti-parasitics, and treatments for Parkinson's and other conditions) exclusively for Brazil's public health system (SUS). It conducts pharmaceutical R&D including fixed-dose combinations, pediatric formulations, and novel drug candidates for neglected tropical diseases, and supplies 100% of Ministry of Health purchase orders for its portfolio from a manufacturing complex in Rio de Janeiro.

Product overview

Farmanguinhos / Fiocruz is the Federal Pharmaceutical Laboratory and Official Laboratory of Brazil's Ministry of Health, operating as a public pharmaceutical manufacturer. The institution produces a comprehensive portfolio of essential medicines including: nine antiretroviral medications for HIV/AIDS (such as Dolutegravir+Lamivudine, Efavirenz, Zidovudine, Atazanavir); four tuberculosis medications (including the 4-in-1 fixed-dose combination); three malaria treatments (including Artesunate+Mefloquine); Praziquantel and Arpraziquantel for schistosomiasis; Nifurtimox for Chagas disease; Pramipexol for Parkinson's disease; and Dietilcarbamazina for filariasis. The institute also operates the Centro de Inovação em Biodiversidade e Saúde (CIBS) developing phytomedicines and biodiversity-based pharmaceuticals, and publishes the scientific journal Revista Fitos.

Differentiator

Problem solved

Functional benefit

Products and services

• Dolutegravir 50mg + Lamivudina 300mg
• Antiretroviral Portfolio
• Tuberculosis Medications (Tuberculostáticos)
• Malaria Medications
• Arpraziquantel (Pediatric Praziquantel)
• Pramipexol (Dichloridrato de Pramipexol)
• Nifurtimox
• Dietilcarbamazina
• Entricitabina + Fumarato de Tenofovir Desoproxila (PrEP)
• CIBS Fitomedicamentos (Phytomedicines Innovation Center)

Quantifiable outcome

• Dolutegravir 50mg + Lamivudina 300mg simplified daily single-tablet regimen reduces toxicity and adverse effects compared to multi-drug HIV regimens
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

30 partnerships are on record, tiered secondary, core and minor.

• Universidade Lusófona (Portugal)secondaryStrategic or Co-development Partner · 3 February 2026Memorandum of understanding signed for research, development, and innovation in health between Fiocruz/Farmanguinhos and the Portuguese university, aimed at international scientific cooperation in pharmaceutical technology and public health.
• Bayer AGcoreStrategic or Co-development Partner · 4 December 2023Technical and scientific cooperation agreement for ANVISA registration of a generic clone medication for Chagas disease (Nifurtimox) to be supplied through SUS. Farmanguinhos will handle the regulatory registration process for marketing authorization in Brazil, with potential future technology transfer for domestic production.
• ViiV Healthcare Company and GlaxoSmithKline (GSK)coreStrategic or Co-development Partner · 1 July 2020Strategic alliance for development, technology transfer, and supply of Dolutegravir 50mg + Lamivudina 300mg antiretroviral combination to SUS. Signed July 2020. Farmanguinhos is acquiring full domestic production autonomy including dual-layer tablet platform technology. ANVISA approved Farmanguinhos' registration in May 2022.
• Pediatric Praziquantel Consortium (Consórcio Praziquantel para Uso Pediátrico)coreStrategic or Co-development PartnerInternational public-private partnership to develop, register, and provide access to pediatric Arpraziquantel for treating schistosomiasis in pre-school children (3 months to 6 years). Funded by Merck with contributions from Bill & Melinda Gates Foundation, GHIT Fund, and EDCTP. Farmanguinhos serves as one of two planned manufacturing sites (also Kenya Medical Research Institute / Universal Corporation). EMA issued positive scientific opinion in December 2023.
• Merck KGaA (Germany)coreTechnology or IntegrationTechnology partner in the Pediatric Praziquantel Consortium. Optimized the pediatric praziquantel formulation and provided manufacturing process parameters. Farmanguinhos produced clinical trial materials and hosts engineering batch manufacturing visits. Merck sends regulatory submission letter to EMA and coordinates the development program.
• Astellas Pharma (Japan)coreTechnology or IntegrationOriginal developer of the pediatric praziquantel prototype formulation. Contributed intellectual property and formulation expertise to the Pediatric Praziquantel Consortium for advancement toward global registration.
• Universidade de Aveiro (Portugal)secondaryStrategic or Co-development PartnerCollaboration between Farmanguinhos/Fiocruz and the University of Aveiro for international cooperation in health systems, public health promotion, and access to health, through joint seminars and knowledge exchange between Brazil and Portugal.
• Universidade de Coimbra (Portugal)secondaryStrategic or Co-development PartnerCooperation agreement signed with the University of Coimbra as part of Farmanguinhos' internationalization strategy, focusing on academic and scientific collaboration in pharmaceutical sciences and health innovation.
• Universidade Federal do Rio de Janeiro (UFRJ)secondaryStrategic or Co-development PartnerPartnership in pharmaceutical research including co-infection cell model development (HIV-tuberculosis, HIV-cryptococcosis) and collaboration on a National Reference Center in Pharmochemistry being established in Rio de Janeiro.
• Fiocruz (Instituto de Tecnologia em Imunobiológicos - Bio-Manguinhos)coreStrategic or Co-development PartnerSister Fiocruz unit with which Farmanguinhos shares the Manguinhos campus. Joint academic year opening events and cross-institutional educational activities. Both units collaborate on public health pharmaceutical supply and research.
• The Johns Hopkins Medical School (USA)secondaryStrategic or Co-development PartnerInternational research collaboration for development of co-infection cell models (HIV-tuberculosis) and scientific exchange in pharmaceutical research methodology.
• WHO / PAHOcoreStrategic or Co-development PartnerFarmanguinhos products contribute to WHO prequalification and PAHO regional pharmaceutical supply programs. EMA's EU-M4all procedure for pediatric praziquantel involves cooperation with WHO. PAHO Strategic Fund relies on Farmanguinhos as a regional supplier.
• ANVISA (Brazilian Health Regulatory Agency)coreStrategic or Co-development PartnerBrazil's national health regulatory agency that registers and prequalifies Farmanguinhos products. ANVISA designated Farmanguinhos' pramipexol as a national reference drug and is the agency through which Farmanguinhos pursues regulatory approvals for all its pharmaceutical products.
• EMA (European Medicines Agency)coreStrategic or Co-development PartnerEMA issued a positive scientific opinion (EU-M4all procedure) for pediatric Arpraziquantel in December 2023, serving as the basis for WHO prequalification and enabling regulatory submissions in endemic countries. Farmanguinhos is the manufacturing partner for Brazil.
• Lygature (Netherlands)minorStrategic or Co-development PartnerConsortium partner in the Pediatric Praziquantel Consortium providing consortium management and coordination services for the international public-private partnership.
• Swiss Tropical and Public Health Institute (Switzerland)minorStrategic or Co-development PartnerResearch partner in the Pediatric Praziquantel Consortium contributing expertise in tropical medicine and public health for the development of treatments for schistosomiasis in children.
• Unlimit Health (United Kingdom)minorStrategic or Co-development PartnerConsortium partner in the Pediatric Praziquantel Consortium working on schistosomiasis elimination and access to health for affected populations.
• Kenya Medical Research Institute (KEMRI, Kenya)minorStrategic or Co-development PartnerConsortium partner and one of the planned manufacturing sites (alongside Farmanguinhos) for pediatric praziquantel, preparing local production capacity for Africa distribution.
• Université Félix Houphouët-Boigny (Côte d'Ivoire)minorStrategic or Co-development PartnerAcademic research partner in the Pediatric Praziquantel Consortium contributing to the development program from Côte d'Ivoire.
• Klinikum rechts der Isar, TU München (Germany)minorStrategic or Co-development PartnerResearch partner in the Pediatric Praziquantel Consortium contributing clinical research expertise.
• Ministry of Health of Côte d'IvoireminorStrategic or Co-development PartnerHealth ministry partner in the Pediatric Praziquantel Consortium from Côte d'Ivoire contributing regulatory and implementation expertise.
• African Institute for Health and Development (Kenya)minorStrategic or Co-development PartnerPartner in the Pediatric Praziquantel Consortium contributing to implementation and access strategies for pediatric schistosomiasis treatment in Africa.
• Massey University (New Zealand)minorStrategic or Co-development PartnerCollaboration through the Global Competence Certificate (GCC) intercultural program, with four Farmanguinhos collaborators completing the program and receiving the title of Global Citizens.
• Fiocruz ICTB (Instituto de Ciência e Tecnologia em Biomodelos)secondaryStrategic or Co-development PartnerCollaboration on preclinical testing of latency-reversing agent candidates from medicinal plant latex in non-human primates (rhesus monkeys), advancing the HIV functional cure research program.
• CNPq (Brazilian National Council for Scientific and Technological Development)coreStrategic or Co-development PartnerGovernment research funding agency that supports Farmanguinhos' scientific initiation programs, graduate programs, and research groups through the PIBIC/PIBITI institutional scholarship programs.
• FAPERJ (Carlos Chagas Filho Foundation for Research Support in Rio de Janeiro)coreStrategic or Co-development PartnerState research funding agency supporting Farmanguinhos researchers and graduate students through scholarship programs and research grants, including participation in the Scientific Initiation Annual Meeting.
• FINEP (Brazilian Innovation Agency)coreStrategic or Co-development PartnerFederal innovation agency providing funding for Farmanguinhos' technology development projects, pharmaceutical innovation, and industrial pharmaceutical technology programs.
• DNDi (Drugs for Neglected Diseases initiative)coreStrategic or Co-development PartnerNon-profit pharmaceutical research organization focused on developing treatments for neglected diseases. Listed as a partner on Farmanguinhos' institutional partners page.
• MMV (Medicines for Malaria Venture)coreStrategic or Co-development PartnerNon-profit product development partnership focused on malaria drug development. Listed as an institutional partner on Farmanguinhos' website.
• Fiocruz VPPCB (Vice-Presidência de Pesquisa e Coleções Biológicas)secondaryStrategic or Co-development PartnerFiocruz vice-presidency that supported the development of the medicinal plant database through the Herbarium of Medicinal Plants Collection (CBPM) at CIBS/Farmanguinhos.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Aspen Pharmacare: South African pharmaceutical company with a major presence in generic ARVs, vaccines, and critical medicines for African public health systems. Comparable role as a regional supplier to government procurement programs serving low- and middle-income countries.
• Hetero Labs: Indian generic pharmaceutical manufacturer with a leading global position in ARV production and technology transfer partnerships with multinational innovators. Comparable ARV product portfolio and reliance on tech transfer arrangements.
• BioCubaFarma: Cuban state-owned pharmaceutical and biotech conglomerate producing essential medicines, vaccines, and biopharmaceuticals for Cuba's public health system and export markets. Similar public-sector pharma mission with broader biologics and biotech portfolio.
• Cipla: Indian generic pharmaceutical company with one of the world's largest ARV portfolios and a long history of supplying HIV/AIDS medicines to global public health programs (Global Fund, PEPFAR). Closest private-sector peer by therapeutic focus on public-health essential medicines.

Direct peers

• Bio-Manguinhos (Instituto de Tecnologia em Imunobiológicos): Sister Fiocruz unit producing vaccines and biologics for the Brazilian Ministry of Health. Operates the same government procurement model, shares the Manguinhos campus, and has an overlapping mandate of supplying SUS with strategic immunological products.
• Instituto Butantan: São Paulo state-owned pharmaceutical laboratory producing vaccines, antivenoms, and diagnostics for Brazil's public health system. Most direct Brazilian comparator as another state-level public pharma lab with a comparable essential-medicines portfolio.
• BIRMEX (Laboratorios de Biológicos y Reactivos de México): Mexican state-owned pharmaceutical laboratory producing vaccines and biologicals for the Mexican public health system. Closest Latin American peer operating under an analogous government-owned pharmaceutical manufacturing model with comparable mission.

Others

• Medicines for Malaria Venture (MMV): Product development partnership focused on malaria drug development. Listed institutional partner of Farmanguinhos; functions as a co-developer and funder for malaria therapeutics, not a direct manufacturing competitor.
• DNDi (Drugs for Neglected Diseases initiative): International non-profit R&D organization developing treatments for neglected tropical diseases. Listed partner of Farmanguinhos in NTD drug development and aligned on the public-health drug development mandate; functions as a research partner and ecosystem participant rather than direct competitor.

Regional players

• Haffkine Bio-Pharmaceutical Corporation: Indian state-owned pharmaceutical manufacturer producing vaccines, sera, and anti-snake-venom for India's public health system. Comparable state-owned pharma lab model serving a national public procurement mandate, but operating in a different geography.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Farmanguinhos_
• YouTubeyoutube.com/@FarmanguinhosFiocruzOficial
• Facebookfacebook.com/Farmanguinhos
• LinkedInlinkedin.com/company/farmanguinhosoficial

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Farmanguinhos / Fiocruz